India's Biopharma Sector Needs Government Risk-Sharing for Growth

India's biopharma sector has grown a lot in the last ten years, but private companies aren't investing enough in research.

Rajesh Jain, a leader in the field, says the government needs to help share the risk so companies can invest more.

Right now, vaccines are a big part of the sector, but other areas like biologics and gene therapies are also important.

The weak rupee might help because India exports a lot of vaccines.

There are many new biotech startups, but they often struggle to get enough money to grow.

Finally, artificial intelligence is starting to be used in making medicines, but it's still new and not perfect yet.